Oral Oncology
Volume 40, Issue 8 , Pages 804-810 , September 2004

Expression of tumor necrosis factor-alpha and its soluble receptors in betel-quid-chewing patients at different stages of treatment for oral squamous cell carcinoma

  • Tzu-Rong Su

      Affiliations

    • Graduate Institute of Dental Sciences, Kaohsiung Medical University, Kaohsiung 807, Taiwan
    • Tian-Sheng Memorial Hospital, Tong-Kang 928, Taiwan
    • ,
  • Kee-Lung Chang

      Affiliations

    • Department of Biochemistry, Kaohsiung Medical University, Kaohsiung 807, Taiwan
    • ,
  • Chien-Hung Lee

      Affiliations

    • Graduate Institute of Public Health, Kaohsiung Medical University, Kaohsiung 807, Taiwan
    • ,
  • Chung-Ho Chen

      Affiliations

    • Department of Oral and Maxillofacial Surgery, Kaohsiung Medical University, Kaohsiung 807, Taiwan
    • ,
  • Yi-Hsin Yang

      Affiliations

    • Graduate Institute of Oral Health Sciences, Kaohsiung Medical University, Kaohsiung 807, Taiwan
    • ,
  • Tien-Yu Shieh

      Affiliations

    • Oral Health Research Center, Collage of Dental Medicine, Kaohsiung Medial University, No. 100 Shih-Chuan 1st Rd, Kaohsiung 807, Taiwan
    • Corresponding Author InformationCorresponding author. Tel.: +886-7-312-1101x2338; fax: +886-7-322-3870

Received 28 January 2004 ,Accepted 3 February 2004.

References 

  1. Shaffer D, Fisher P, Dulcan MK, Davies M, Piacentini J, Schwab-Stone ME, et al.  The NIMH diagnostic interview schedule for children version 2.3 (DISC-2.3): description, acceptability, prevalence rates, and performance in the MECA study. Methods for the epidemiology of child and adolescent mental disorders study. J. Am. Acad. Child Adolesc. Psychiatry. 1996;35(7):865–877
  2. Cancer registry. Department of Health, Taiwan, Republic of China, 1996
  3. Silverman S, Gorsky M. Epidemiologic and demographic update in oral cancer: California and national data––1973 to 1985. J. Am. Dent. Assoc. 1990;120(5):495–499
  4. Nagler RM. Molecular aspects of oral cancer. Anticancer Res. 2002;22(5):2977–2980
  5. Fernandez-Botran R. Soluble cytokine receptors: their role in immunoregulation. FASEB J. 1991;5(11):2567–2574
  6. Jablonska E, Kiluk M, Piotrowski L, Grabowska Z, Markiewicz W, Jablonski J. Tumor necrosis factor-alpha and soluble tumor necrosis factor receptors in the culture supernatants of polymorphonuclear cells and peripheral blood mononuclear cells from cancer patients. Eur. Cytokine Netw. 1998;9(2):155–159
  7. Beutler B, Cerami A. Tumor necrosis, cachexia, shock, and inflammation: a common mediator. Annu. Rev. Biochem. 1988;57:505–518
  8. Gallo O, Pinto S, Boccuzzi S. Monocyte tumor necrosis factor production in head and neck squamous cell carcinoma. Laryngoscope. 1992;102(4):447–450
  9. Parks RR, Yan SD, Huang CC. Tumor necrosis factor-alpha production in human head and neck squamous cell carcinoma. Laryngoscope. 1994;104(7):860–864
  10. Aggarwal BB, Natarajan K. Tumor necrosis factors: developments during the last decade. Eur. Cytokine Netw. 1996;7(2):93–124
  11. Oppenheim JJ, Feldmann M. Cytokine reference: a compendium of cytokine and other mediators of host defense. In:  Aggarwal BB,  Samanta A,  Feldmann M editor. TNF Receptors. London: Academic Press; 2001;p. 1619–1632
  12. Nophar Y, Kemper O, Brakebusch C, Englemann H, Zwang R, Aderka D, et al.  Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor. EMBO J. 1990;9(10):3269–3278
  13. Porteu F, Nathan C. Shedding of tumor necrosis factor receptors by activated human neutrophils. J. Exp. Med. 1990;172(2):599–607
  14. Smith KJ, Skelton HG. Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor alpha receptor IgG1-Fc fusion complex therapy. J. Am. Acad. Dermatol. 2001;45(6):953–956
  15. Girardin E, Roux-Lombard P, Grau GE, Suter P, Gallati H, Dayer JM. Imbalance between tumour necrosis factor-alpha and soluble TNF receptor concentrations in severe meningococcaemia. Immunology. 1992;76(1):20–23
  16. Aggarwal S, Gollapudi S, Gupta S. Increased TNF-alpha-induced apoptosis in lymphocytes from aged humans: changes in TNF-alpha receptor expression and activation of caspases. J. Immunol. 1999;162(4):2154–2161
  17. Powell JL, Strauss KA, Wiley C, Zhan M, Morris JG. Inflammatory cytokine response to Vibrio vulnificus elicited by peripheral blood mononuclear cells from chronic alcohol users is associated with biomarkers of cellular oxidative stress. Infect. Immunol. 2003;71(7):4212–4216
  18. Zhao XJ, Marrero L, Song K, Oliver P, Chin SY, Simon H, et al.  Acute alcohol inhibits TNF-alpha processing in human monocytes by inhibiting TNF/TNF-alpha-converting enzyme interactions in the cell membrane. J. Immunol. 2003;170(6):2923–2931
  19. Ryder MI, Saghizadeh M, Ding Y, Nguyen N, Soskolne A. Effects of tobacco smoke on the secretion of interleukin-1beta, tumor necrosis factor-alpha, and transforming growth factor-beta from peripheral blood mononuclear cells. Oral. Microbiol. Immunol. 2002;17(6):331–336
  20. Fiers W. Tumor necrosis factor. Characterization at the molecular, cellular and in vivo level. FEBS Lett. 1991;285(2):199–212
  21. Palladino MA, Shalaby MR, Kramer SM, Ferraiolo BL, Baughman RA, Deleo AB, et al.  Characterization of the antitumor activities of human tumor necrosis factor-alpha and the comparison with other cytokines: induction of tumor-specific immunity. J. Immunol. 1987;138(11):4023–4032
  22. Naylor MS, Stamp GW, Foulkes WD, Eccles D, Balkwill FR. Tumor necrosis factor and its receptors in human ovarian cancer. Potential role in disease progression. J. Clin. Invest. 1993;91(5):2194–2206
  23. Frater-Schroder M, Risau W, Hallmann R, Gautschi P, Bohlen P. Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo. Proc. Natl. Acad. Sci. USA. 1987;84(15):5277–5281
  24. Mannel DN, Ruschoff J, Orosz P. The role of TNF in tumour growth and metastasis. Res. Immunol. 1993;144(5):364–369
  25. Aderka D, Engelmann H, Wysenbeek AJ, Levo Y. The possible role of tumor necrosis factor (TNF) and its natural inhibitors, the soluble-TNF receptors, in autoimmune diseases. Isr. J. Med. Sci. 1992;28(2):126–130
  26. Oppenheim JJ, Feldmann M. Cytokine reference: a compendium of cytokine and other mediators of host defense. In:  Feldmann M,  Brennan FM editor. Cytokines and disease. London: Academic Press; 2001;p. 35–51
  27. Elsasser-Beile U, von Kleist S, Sauther W, Gallati H, Monting JS. Impaired cytokine production in whole blood cell cultures of patients with gynaecological carcinomas in different clinical stages. Br. J. Cancer. 1993;68(1):32–36
  28. Jablonska E. Soluble IL-6 and TNF receptors release by polymorphonuclear and mononuclear cells in cancer patients. Neoplasma. 1999;46(1):35–39
  29. Dembic Z, Loetscher H, Gubler U, Pan YC, Lahm HW, Gentz R, et al.  Two human TNF receptors have similar extracellular, but distinct intracellular, domain sequences. Cytokine. 1990;2(4):231–237
  30. Aderka D, Englemann H, Hornik V, Skornick Y, Levo Y, Wallach D, et al.  Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients. Cancer Res. 1991;51(20):5602–5607

PII: S1368-8375(04)00047-8

doi: 10.1016/j.oraloncology.2004.02.001

Oral Oncology
Volume 40, Issue 8 , Pages 804-810 , September 2004

Article Tools